Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Prompt recognition and treatment for thrombotic thrombocytopenic purpura (TTP) are critical to prevent the irreversible manifestations of this rare and quickly fatal hematologic disorder. Untreated TTP is typically a rapid-onset disease with mortality exceeding 90% within days in the absence of appropriate treatment. In the current report, we describe a case of immune-mediated TTP (iTTP) in a 62-year-old man manifesting as longstanding thrombocytopenia, recurrent cardioembolic strokes, and valvular thrombogenesis over a period of 3 years. We provide correlative evidence to support the potential contribution of adalimumab, a TNFα inhibitor, to the development of iTTP. We offer several educational insights regarding the identification of atypical presentations of iTTP owing to the longstanding disease course and numerous clinical comorbidities seen in this patient.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507438 | PMC |
| http://dx.doi.org/10.1002/ccr3.4850 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cytokine storm and microvascular fate: mechanistic insights into endothelial injury in thrombotic microangiopathies.
Ann Med Surg (Lond)
September 2025
Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
Thrombotic microangiopathies (TMAs) encompass a diverse group of syndromes marked by microvascular thrombosis, thrombocytopenia, and organ injury, primarily affecting the kidneys and central nervous system. While the etiologies differ-ranging from genetic mutations to infectious and autoimmune triggers-a unifying pathogenic mechanism is endothelial dysfunction. Recent advances have illuminated the pivotal role of cytokine dysregulation in initiating and sustaining this vascular injury.
View Article and Find Full Text PDFShould thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
Res Pract Thromb Haemost
July 2025
Division of Classical Hematology, Mass General Brigham Cancer Institute, Massachusetts General Hospital, Boston, Massachusetts, USA.
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy for solid tumors that results in increased bleeding risk and chemotherapy dose reductions, treatment delays, and agent discontinuation. Unlike other chemotherapy-induced cytopenias, CIT remains without any licensed therapies in most of the world. Multiple thrombopoietin receptor agonists (TPO-RAs) have been approved for other thrombocytopenic indications, however, and are widely available, offering an accessible option for CIT management.
View Article and Find Full Text PDFThromboelastographic assessment of hypofibrinolysis in stored plasma samples: A novel spike-in method.
Thromb Res
August 2025
Institute for Clinical and Experimental Transfusion Medicine, Tuebingen, Germany; Center for Clinical Transfusion Medicine, University Hospital of Tuebingen, Tuebingen, Germany.
Introduction: Congenital or acquired dysregulation of fibrinolytic system can lead to bleeding (hyperfibrinolysis) or thrombosis (hypofibrinolysis), with increased risk for multi-organ failure. Standard clotting-based assays provide limited insight into fibrinolytic status. In contrast, thromboelastography (TEG), a whole blood assay, offers a comprehensive assessment of the coagulation and fibrinolytic systems.
View Article and Find Full Text PDFBNT162b2 COVID-19 vaccination uptake, safety, effectiveness, and waning in children and young people aged 5-11 years in Scotland.
J Glob Health
August 2025
Usher Institute, The University of Edinburgh, Edinburgh, UK.
Background: Few large-scale population studies have examined both safety and vaccine effectiveness (VE) specifically for 5-11-year-olds during the Omicron-dominant period in a setting with low vaccine uptake. The BNT162b2 (Pfizer-BioNTech) vaccine, administered in two doses, has shown strong efficacy against symptomatic and severe COVID-19 in clinical trials involving children and young people (CYP). Accordingly, we examined the uptake, real-world safety, VE, and waning of BNT162b2 VE against symptomatic COVID-19 among children aged 5-11 years in Scotland.
View Article and Find Full Text PDFPrognostic value of laboratory biomarkers for mortality risk stratification in thrombotic thrombocytopenic purpura.
Ann Hematol
August 2025
Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan, 430030, China.
This study aimed to explore the relationship between laboratory indicators and short-term mortality risk in patients with thrombotic thrombocytopenic purpura (TTP) and to construct a risk stratification model. We retrospectively analyzed the clinical data of 106 patients with TTP admitted to Tongji Hospital between June 2016 and February 2025. Patients were grouped by 28-day survival: death (n = 45) and survival (n = 61).
View Article and Find Full Text PDF